Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

NCT01453998 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01453998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01453998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
October 14, 2011
Completion date
November 12, 2012
Enrollment
657 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, haemophilus influenzae type b, hepatitis b, poliomyelitis, tetanus